Accute Lymphoblastic Leukemia (Pediatric)

Acute lymphoblastic leukemia (ALL) makes up 75% of childhood leukemia diagnoses.¹ Treatment of the disease represents one of the greatest success stories in cancer research to date: since the 1960s, the survival rate has climbed from less than 10% to over 90%.2 Despite this remarkable progress, a few high-risk subgroups still suffer poor clinical outcome. These groups are characterized primarily by their genetic profiles, with certain chromosomal lesions conferring a higher risk of disease progression.3 Understanding the role of these mutations in ALL development will continue to serve as an active area of investigation in the research and clinical communities.